bupivacaine microsphere (ND-340) / Nang Kuang Pharma - LARVOL DELTA

A Phase I Study to Evaluate the Safety and PK of ND-340 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: Nang Kuang Pharmaceutical Co., Ltd. | Recruiting ➔ Completed | N=40 ➔ 24 | Trial completion date: Dec 2024 ➔ Mar 2024 | Trial primary completion date: Dec 2024 ➔ Mar 2024

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Pain

A Phase I Dose-escalation Study of a Single Administration of Extended-Release Injectable Suspension (ND-340) (clinicaltrials.gov) - P1 | N=36 | Suspended | Sponsor: Nang Kuang Pharmaceutical Co., Ltd. | Trial completion date: Mar 2024 ➔ Jun 2026 | Trial primary completion date: Dec 2023 ➔ Dec 2025

Trial completion date • Trial primary completion date • Orthopedics • Pain

A Phase I Study to Evaluate the Safety and PK of ND-340 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Nang Kuang Pharmaceutical Co., Ltd. | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Jun 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • Pain

A Phase I Study to Evaluate the Safety and PK of ND-340 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Nang Kuang Pharmaceutical Co., Ltd.

New P1 trial • Pain

A Phase I Dose-escalation Study of a Single Administration of Extended-Release Injectable Suspension (ND-340) (clinicaltrials.gov) - P1 | N=36 | Suspended | Sponsor: Nang Kuang Pharmaceutical Co., Ltd. | Trial completion date: Mar 2022 ➔ Mar 2024 | Recruiting ➔ Suspended | Trial primary completion date: Dec 2021 ➔ Dec 2023

Trial completion date • Trial primary completion date • Trial suspension • Orthopedics • Pain